Eparlitozoviril as Adjuvant Therapy for Resectable HCC With MVI

NCT07658105 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

HCC - Hepatocellular Carcinoma

Interventions

DRUG: eparlitozoviril
OTHER: Control group

Sponsor

Tianjin Medical University Cancer Institute and Hospital